Bausch Health Companies (NYSE:BHC shareholders incur further losses as stock declines 4.4% this week, taking three-year losses to 72%
Bausch Health Companies Inc. ( NYSE:BHC ) shareholders should be happy to see the share price up 26% in the last ...
Bausch + Lomb Shares Rise on FDA Approval of enVista Envy Intraocular Lens
Shares in Bausch + Lomb were higher after the company received approval from the Food and Drug Administration for its enVista Envy full range of vision intraocular lens. Shares were recently up 23% at ...
Pharmabiz47m
Bausch + Lomb receives US FDA approval for enVista Envy full range of vision intraocular lens
Bausch + Lomb receives US FDA approval for enVista Envy full range of vision intraocular lens: Vaughan, Ontario Tuesday, October 15, 2024, 17:00 Hrs [IST] Bausch + Lomb Corporatio ...
ophthalmologytimes15h
Anthony Wallace of Bausch + Lomb talks about enVista Envy FDA approval
The FDA granted approval to the enVista Envy full range of vision IOLs following Canadian approval in May 2024.
FiercePharma6d
Bausch + Lomb taps broadcaster Erin Andrews to push fast-growing dry eye disease drug
Bausch + Lomb has teamed up with American sportscaster Erin Andrews to promote its dry eye disease treatment, launching the ...
Bausch + Lomb : FDA Approves EnVista Envy Full Range Of Vision Intraocular Lens
Bausch + Lomb Corp. (BLCO, BLCO.TO) announced that the U.S. Food and Drug Administration has approved the enVista Envy full range of ...
ophthalmologytimes23h
FDA approves Bausch + Lomb’s enVista Envy range of IOLs
According to the company, enVista Envy IOLs will be commercially available in the U.S. on a limited basis in the coming weeks ...